Efficacia delle varie modalità di terapia dell’ipertiroidismo del morbo di Basedow: revisione sistematica e meta-analisi

Sundaresh, Vishnu; Brito, João Pedro Azeredo de; Wang, Z.; Prokop, L.; Stan, Marius N.; Murad, Muhammad; Bahn, Rebecca S.; Marinò, Michele

doi:10.1007/bf03346106

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Niestety, mimo leczenia może dojść do nawrotu objawów, czynnikami predykcyjnymi braku remisji są: płeć męska, masywne wole, ciężka nadczynność tarczycy oraz wcześniejsze nawroty choroby [29]. β-blokery są stosowane w skojarzeniu z tyreostatykami w celu złagodzenia objawów tyreotoksykozy [30,31]. U pacjentów ze współistniejącą astmą oskrzelową zaleca się stosowanie leków β1-selektywnych.…”

Section: Leczenie Farmakologiczneunclassified

What kind of therapeutic solutions for Graves’ disease does modern medicine propose? - a review of the literature

WOŚ

SZALA-CZERWONKA

REJMER

et al. 2023

J Educ Health Sport

View full text Add to dashboard Cite

Background: Graves' disease is responsible for 60-80% causes of hyperthyreosis. An important role in the pathogenesis is played by anti-TSHR immunoglobulins (TRAb), that stimulate TSH receptors leading to excessive hormone synthesis and release by the gland. The aim of the study: This study was designed to summarise the current state of knowledge on the diagnosis, pathogenesis and methods of treatment used for Graves' disease. Materials and methods: We reviewed the literature available in the PubMed database using the following keywords: "Graves' disease", "Graves' pathogenesis", "Graves' diagnosis", "Graves' treatment”. Results: Graves' disease develops as a result of as well genetic as environmental factors. The diagnosis is based on physical examination, and laboratory & imaging studies. Several therapeutic options are currently used. Pharmacotherapy with thyreostatics is used either as a stand-alone method or as a preparation for a radical treatment - radioactive iodine ablation and thyroidectomy, which is the surgical removal of the gland. The treatment form is recommended to be selected individually depending on each patient, indications and co-morbidities. Developing research into the etiology of the disease is an opportunity to develop newer and efficient methods of causal treatment. Summary: Graves' disease is an autoimmune thyroid disorder with a multiple factor etiology. A variety of therapeutic approaches are currently used: treatment with antithyrodid drugs, radioactive iodine ablation and the surgical resection of the thyroid gland. A more detailed understanding of the mechanisms causing the development of the disease offers prospects for the creation of innovative and more efficient therapeutic modalities.

show abstract

Section: Leczenie Farmakologiczneunclassified

What kind of therapeutic solutions for Graves’ disease does modern medicine propose? - a review of the literature

WOŚ

SZALA-CZERWONKA

REJMER

et al. 2023

J Educ Health Sport

View full text Add to dashboard Cite

show abstract

“…Although geographical difference exists, ATD is the preferred first-line therapy in most areas due to its safety and easy accessibility (5,6). However, compared with RAI therapy or surgery, characterized by a relatively more definite treatment, the major clinical issue with ATD is always the risk of recurrence when therapy is discontinued (7,8).…”

Section: Introductionmentioning

confidence: 99%

Long-term follow-up result of antithyroid drug treatment of Graves’ hyperthyroidism in a large cohort

Jin

Jang

Kim

et al. 2023

European Thyroid Journal

View full text Add to dashboard Cite

Objective: This study evaluated the efficacy of antithyroid drugs (ATD) and risk factors associated with the recurrence of Graves’ hyperthyroidism using a comprehensive retrospective cohort. Methods: We included 1,829 patients newly diagnosed with Graves’ hyperthyroidism, with sufficient follow-up data. Clinical outcomes of the patients and risk factors associated with recurrence-free survival, including the changes in thyrotropin receptor antibody, were evaluated. Results: The median age of the patients was 44.5 years, and 69% were female. Among the patients, 1,235 had a chance to withdraw ATD after a median of 23 (interquartile range [IQR] 17.0–35.5) months of treatment. The first remission rate was 55.6% during a median of 72.7 months of follow-up. After the first recurrence, 95% of patients underwent the second course of ATD treatment for a median of 21.1 (IQR 14.8–31.7) months, and the remission rate was 54.1%. During a median of 67 months of follow-up, 7.7% of patients underwent surgery, and 10.5% underwent radioactive iodine therapy. Approximately 30% were still on ATD therapy for recurrent disease or prolonged low-dose maintenance. Younger age (< 45 years), male sex, and fluctuating or smoldering of TRAb levels were independent risk factors of the first recurrence after ATD treatment. Conclusions: ATD treatment is an acceptable option for the initial treatment of Graves’ hyperthyroidism, as well as for recurrent disease. The optimal treatment period for ATD treatment needs to be determined using the individual risk factors of recurrence.

show abstract

Efficacia delle varie modalità di terapia dell’ipertiroidismo del morbo di Basedow: revisione sistematica e meta-analisi

Cited by 2 publications

References 0 publications

What kind of therapeutic solutions for Graves’ disease does modern medicine propose? - a review of the literature

What kind of therapeutic solutions for Graves’ disease does modern medicine propose? - a review of the literature

Long-term follow-up result of antithyroid drug treatment of Graves’ hyperthyroidism in a large cohort

Contact Info

Product

Resources

About